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Introduction
Chronic lymphocytic leukemia (CLL) with defective DNA
damage response (DDR) is refractory to conventional
chemotherapeutics.1 The loss of DDR occurs through inacti-
vation of ATM and TP53 genes.2 ATM mutations appear in
13%-16% of CLLs and are distributed across a large coding
region encompassing 64 exons.3,4 The loss of ATM function
typically occurs through the combined effect of 11q deletion
(monoalleic ATM loss) and an ATM mutation, biallelic ATM
mutations, or less frequently due to the presence of a single
mutation, capable of exerting dominant-negative effect on
the remaining ATM allele.3,4 Compared to CLL tumors with
11q deletion only, those with inactivation of both ATM alle-
les exhibit abrogated DNA damage-induced apoptotic
responses in vitro and rapid clonal expansion in vivo, leading
to reduced overall and treatment-free survival.1 Furthermore,
in the phase III UK CLL4 trial that compared chlorambucil
with fludarabine either alone or in combination with
cyclophosphamide, CLL patients with biallelic ATM inactiva-
tion revealed progression-free survival inferior to tumors
with a single mutation or 11q deletion, which was second
only to tumors with loss/mutation of both TP53 alleles.5
Early cytogenetic studies showed that CLL progression is
associated with the emergence of 11q deleted subclones.6
More recent reports of the dynamic nature of clonal progres-
sion has led to the understanding that the selective pressure
imparted by DNA damaging agents favors the expansion of
pre-existing subclones with defective DDR and consequently
successive rounds of treatment with these agents are less
effective.7,8 There is, therefore, a need for therapeutic strate-
gies that act independently of the DDR pathway that can tar-
get ATM-null CLL cells. 
ATM is a serine/threonine protein kinase activated by
DNA double strand breaks (DSBs) that co-ordinates the acti-
vation of cell cycle checkpoints, DNA repair and p53-depen-
dent apoptosis.9 ATM phosphorylates numerous substrates
and is involved in the regulation of a wide range of cellular
processes. Consequently, deficiencies in any of these
processes caused by the loss of ATM could be used as thera-
peutic targets.10,11 Consistent with this notion, ATM-null CLL
cells are defective in homologous recombination repair
(HRR), a deficiency that can be exploited to induce tumor-
specific killing via enhanced requirement for HRR upon
PARP-inhibition.11
ATM is also implicated in redox homeostasis.12
Deregulation of redox homeostasis results in oxidative stress
and occurs either due to increased reactive oxygen species
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Inactivation of the Ataxia Telangiectasia Mutated gene in chronic lymphocytic leukemia results in resistance to
p53-dependent apoptosis and inferior responses to treatment with DNA damaging agents. Hence, p53-indepen-
dent strategies are required to target Ataxia Telangiectasia Mutated-deficient chronic lymphocytic leukemia. As
Ataxia Telangiectasia Mutated has been implicated in redox homeostasis, we investigated the effect of the Ataxia
Telangiectasia Mutated-null chronic lymphocytic leukemia genotype on cellular responses to oxidative stress with
a view to therapeutic targeting. We found that in comparison to Ataxia Telangiectasia Mutated-wild type chronic
lymphocytic leukemia, pro-oxidant treatment of Ataxia Telangiectasia Mutated-null cells led to reduced binding of
NF-E2 p45-related factor-2 to antioxidant response elements and thus decreased expression of target genes.
Furthermore, Ataxia Telangiectasia Mutated-null chronic lymphocytic leukemia cells contained lower levels of
antioxidants and elevated mitochondrial reactive oxygen species.  Consequently, Ataxia Telangiectasia Mutated-
null chronic lymphocytic leukemia, but not tumors with 11q deletion or TP53 mutations, exhibited differentially
increased sensitivity to pro-oxidants both in vitro and in vivo. We found that cell death was mediated by a p53- and
caspase-independent mechanism associated with apoptosis inducing factor activity. Together, these data suggest
that defective redox-homeostasis represents an attractive therapeutic target for Ataxia Telangiectasia Mutated-null
chronic lymphocytic leukemia.
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ABSTRACT
(ROS) production or reduced antioxidant capacity. A prin-
ciple antioxidant pathway is regulated by the redox sen-
sitive transcription factor, NF-E2 p45-related factor-2
(NRF2/NFE2L2). In unstressed cells, low levels of NRF2
are maintained through interaction with Kelch-like ECH-
associated protein 1 (KEAP1), an adapter for the E3 ubiq-
uitin ligase Cullin 3 (CUL3) that directs NRF2 for protea-
somal degradation.13 Modification of redox and elec-
trophile sensitive cysteine residues inhibits the substrate
adaptor activity of KEAP1 allowing NRF2 accumulation.
The interaction of KEAP1 with NRF2 is further modulat-
ed by phosphorylation of NRF2 at serine 40 by protein
kinase C (PKC).14 Within the nucleus, NRF2 forms het-
erodimers with v-maf musculoaponeurotic fibrosarcoma
oncogene homolog (MAF) proteins (MAF-F, G and K) and
binds to antioxidant response elements (AREs) in the pro-
moters of target genes such as those required for glu-
tathione synthesis and its own promoter.15 This activity is
regulated by the transcriptional repressor BTB and CNC
homology 1 transcription factor (BACH1) which com-
petes for the MAF binding partners and for binding to
gene promoters.16 In addition, genetic models suggest that
binding of Nrf-2 and its activity are regulated by the ATM
substrate, Brca1.17
The most compelling evidence for the role of ATM in
redox homeostasis comes from studies of the human
radiosensitivity syndrome, Ataxia Telangiectasia (A-T),
where both ATM alleles are inactivated. Cells from these
patients display increased oxidative stress as a conse-
quence of elevated levels of ROS, increased
oxidized/reduced glutathione (GSSG/GSH) ratio, dimin-
ished capacity to scavenge ROS and mitochondrial dys-
function.12,18 Furthermore, ATM is directly activated by
oxidative stress19 and can exert antioxidant activity
through regulation of the pentose-phosphate pathway.20
Recent evidence suggests that ATM might regulate oxida-
tive stress through NRF2. Namely, Nrf2 target gene
expression was decreased in Atm-/- murine osteoblasts
and this was rescued by the ectopic expression of PKC
delta (PKCδ).21 
In this study, we tested the hypothesis that ATM-null
CLLs have an intrinsic defect in their antioxidant defenses
that might be exploited to induce synthetic lethality of
tumor cells by escalating oxidative stress. We show that
compared to ATM-wild type (wt) CLL, ATM-null CLL
tumors exhibited defective NRF2-dependent antioxidant
transcriptional responses, decreased antioxidant capacity,
elevated mitochondrial ROS, and increased sensitivity to
pro-oxidants both in vitro and in vivo. Furthermore, we
demonstrate that pro-oxidant treatment bypassed the
need for a functional DRR and induced cell death via a
p53- and caspase-independent mechanism involving
apoptosis inducing factor (AIF).
Methods
Patients’ samples and cell lines 
Chronic lymphocytic leukemia samples were obtained from
Birmingham and Bournemouth Hospitals (Online Supplementary
Table S1). These were comprised of 3 CLLs with monoallelic
ATM loss, 1 monoallelic ATM mutant, 3 biallelic ATM mutants,
5 with combined ATM mutation/deletion and 3 CLLs with TP53
mutations. All patients’ samples contained more than 90%
tumor cells. South Birmingham Ethics Committee granted
approval for the study.  CII, HG3 and PGA isogenic CLL cell
lines expressing short hairpin (sh)-RNA against GFP or ATM
were generated as previously described.11 
Chemicals
H2O2, tert-butylhydroquinone (tBHQ), N-acetyl-p-benzo-
quinone imine (NAPQI) and N-phenylmaleimide were pur-
chased from Sigma-Aldrich (MO, USA), KU-55933 from Merck
(KGaA, Darmstadt, Germany) and Z-VAD-FMK from EnzoLife
Sciences (Exeter, UK). Parthenolide, dimethylamino partheno-
lide (DMAPT) and DMAPT-hydrochloride (DMAPT-HCl) were
isolated and prepared as described (Online Supplementary
Appendix, Online Supplementary Table S2, and Online
Supplementary Figures S1, S2 and S3). 
Quantitative real-time PCR 
SYBR-Green quantitative real-time PCR (Q-PCR) (Life
Technologies) was applied with primers against NRF2, NQO1,
GCLM, GSR and HMOX1 (Online Supplementary Appendix).
Primers against β-ACTIN were used for normalization and
quantification was achieved using the comparative Ct method.22 
XChIP
XChIP was applied to primary CLL samples before and after
treatment with 100 mM tBHQ for 6 h using anti-NRF2 and pre-
immune antisera as previously described23 (Online Supplementary
Appendix).
Biochemical assays
GSH was quantified using a Glutathione Assay Kit (Sigma-
Aldrich).  To determine GSSG, GSH was first derivatized with
N-ethylmaleimide (Sigma-Aldrich). Levels of NADPH and
NADP+ were quantified using an NADP/NADPH assay kit
(Abcam, Cambridge, UK).
Mitochondrial ROS assay
Mitochondrial superoxide was detected using MitoSox Red
(Life Technologies) in accordance with the manufacturer’s
instructions and quantified using an LSR II flow cytometer (BD
Biosciences, Oxford, UK) (Online Supplementary Appendix).
RNA knockdown
Knockdown of gene expression in HaCat cells was achieved
by transfection of siRNAs against ATM, KEAP1, BRCA1 or
Scrambled siRNA with Oligofectamine (Life Technologies) in
accordance with the manufacturer’s instructions (Online
Supplementary Appendix and Online Supplementary Table S4). 
Immunoblotting
Immunoblotting was performed as previously described24
(Online Supplementary Appendix).
Murine xenograft
Animals were treated in accordance with United Kingdom
Home Office guidelines, Schedule 1. Subcutaneous tumors were
initiated by injection of 5x106 CII-isogenic cell lines with and
without stable ATM-knockdown into 6-week old NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. Tumors were grown for 15 days
prior to treatment with 6 mg/kg parthenolide or vehicle via
intra-peritoneal injection for 5 days. 
Primary CLL tumor cells were engrafted as previously
described.25 Briefly, 6-week old NSG mice were sublethally irra-
diated (1.25 Gy) prior to intravenous co-injection of 50x106
PBMC from an ATM-null CLL patient and 10x103 CD14+ mono-
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cytes from a healthy donor. After three days, mice were ran-
domized and treated with a daily dose of either 100 mg/kg
DMAPT-HCl or vehicle by oral gavage for nine days. Splenic
tumor burden was assessed by FACS analysis. 
Statistical analysis
In vitro and in vivo data were analyzed using paired or unpaired
2-tailed Student’s t-tests. Data are presented as ± standard error
of the mean (SEM).
A. Agathanggelou et al.
1078 haematologica | 2015; 100(8)
Figure 1. Induction of the NRF2 antioxidant response is defective in ATM-null CLL primary tumors. (A) Q-PCR showing differentially reduced
induction of transcription of the NRF2-target genes (NRF2, GCLM, NQO1, HMOX1 and GSR) in ATM-wt compared to ATM-null primary CLL sam-
ples following 6 h treatment with 100mM H2O2 and (B) 100mM tBHQ. (C) Q-PCR showing reduced induction of the NRF2 target genes in HaCaT
cells following KEAP1-knockdown with and without ATM-knockdown (n=3) or (D) incubation of KEAP1- knockdown HaCaT cells with 10mM ATM
kinase inhibitor KU-55933 (ATMi) (n=3). The inhibitor was added 48 h after transfection and incubated for 24 h. Data were normalized to β-
ACTIN and expressed as fold-change relative to untreated cells using the comparative Ct method. (E) XChIP assay showing defective tBHQ-
induced binding of NRF2 to ARE in the promoter of NQO1 in ATM-null CLL cells compared to ATM-wt CLLs. XChIP was undertaken in accordance
with the protocol described.23 DNA was immunoprecipitated using anti-NRF2 antibody or pre-immune control. Enriched DNA was amplified
using Q-PCR and data expressed as percentage of input. (F) Q-PCR showing the effect of ATM and BRCA1 knockdowns on tBHQ or (G) H2O2
induced expression of NRF2 target gene NQO1 (n=3). Statistical significance was determined using Student’s t-test. *P<0.05, **P<0.01,
***P<0.001 were considered significant. Error bars represent SEM.
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Results
Defective NRF2-regulated gene expression in ATM-null
CLL cells    
We have investigated the effect of ATM loss on NRF2
directed antioxidant responses by treating a panel of CLL
tumors with H2O2 and measuring the induction of gene
expression by Q-PCR. H2O2 induced a 1.7-3.0 fold
increase in NRF2 target gene expression in ATM-wt
tumors (n=4), whereas induction was significantly
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haematologica | 2015; 100(8) 1079
Figure 2. ATM-null CLL cells exhibit decreased antioxidant content, elevated levels of mitochondrial superoxide and differential sensitivity to
pro-oxidant agents. (A) Total glutathione expressed relative to the levels in ATM wild-type cells are reduced in ATM-null primary CLL samples.
(B) The ratios of GSSG:GSH and (C) NADP+:NADPH are differentially increased in ATM-null primary CLL tumors. (D) Mitochondrial superoxide
measured by flow cytometry is differentially increased in ATM-null CLL tumors treated for 1 h with 0-25mM H2O2. Cells were dual stained with
Annexin V-APC to permit exclusion of double-positive cells undergoing apoptosis. A representative dot plot is shown and (E) quantification is
presented. ATM-null CLL primary tumors show differential sensitivity following treatment with (F) H2O2, (G) NAPQI or (H) parthenolide for 24 h.
The surviving fraction was determined by flow cytometry (Beckman Coulter MCL-Epics flow cytometer) with Annexin V-FITC/propidium iodide
labeling.  The statistical significance was determined using Student’s t-test. *P<0.05, **P<0.01, ***P<0.001 were considered significant.
Error bars represent SEM.
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impaired in ATM-null CLLs (n=4) (Figure 1A).
Examination of previously generated expression data sup-
ported this observation.26 Following exposure to IR, an
insult that generates ROS, upregulation of 40 NRF2 regu-
lated transcripts was significantly (P<0.05) impaired in
ATM-null CLLs (n=6) compared to ATM-wt CLLs (n=5)
(Online Supplementary Figure S4A). 
To investigate a possible role for KEAP1 in the defective
induction of NRF2 target genes in ATM-null CLL, KEAP1
activity was inhibited pharmacologically or by siRNA
knockdown. Tumor cells were treated with tBHQ, the
quinone radical of which is an electrophile that covalently
modifies cysteine residues in KEAP1 preventing it from
targeting NRF2 for degradation. In ATM-wt tumors (n=5),
high-dose tBHQ (100 mM) induced a 5-71 fold upregula-
tion of NRF2 target genes (Figure 1B). In comparison, sig-
nificantly lower expression (0.5-4.3 fold) was induced in
ATM-null tumors (n=5). A similar differential was
observed with low-dose tBHQ (10 µM) indicating that
the defective expression in ATM-null CLLs was not due
to toxicity (Online Supplementary Figure S4B). 
In accordance with a previous report, knockdown of
KEAP1 also induced the expression of NRF2 target
genes.27 Inhibition of ATM function by siRNA-knock-
down (n=3) (Figure 1C) or ATM-inhibitor (n=3) (Figure
1D) abolished induction of NRF2-target genes. These data
indicated that the defective regulation of NRF2 transcripts
in ATM deficient cells occurs downstream of KEAP1 func-
tion. 
Consistent with an absence of a defect in the regulation
of NRF2 by KEAP1 the expression of NRF2 mRNA and
protein was comparable in ATM-wt and ATM-null
tumors (Online Supplementary Figure S4C and D).
Following treatment with tBHQ, no difference was
observed between ATM-wt and ATM-null CLLs regard-
ing the change in levels of NRF2 or other proteins
involved in this antioxidant pathway: KEAP1, BACH1
and MAF protein (Online Supplementary Figure S4D-F). 
A previous study suggested that ATM regulates NRF2
through PKCδ.21 However, in keeping with the data from
a proteomic study of ATM substrates,10 we found no inter-
action between ATM and NRF2 in co-immunoprecipita-
tion assay (Online Supplementary Figure S5A). Furthermore,
we did not detect an interaction between ATM and PKCδ
and loss of ATM did not alter the levels of PKCδ or the
levels of phosphorylated-serine on NRF2 (Online
Supplementary Figure S5B and C).
Brca1 was previously found to regulate Nrf-2 transcrip-
tional activity.17 Therefore, we next investigated the pos-
sibility that ATM co-operates with BRCA1 in the regula-
tion of NRF2 activity. We found reduced induction of
antioxidant genes in cells treated with either ATM or
BRCA1-specific siRNAs (Figure 1F and G). This defect
was not increased by the combined knockdown of both
genes, suggesting ATM and BRCA1 may act in the same
pathway that regulates NRF2 function.
These data suggest that in CLL cells, loss of ATM-func-
tion induces a defect in NRF2 regulated gene expression
that is independent of PKCδ, KEAP1, BACH1 and MAF
proteins and may involve co-operation with BRCA1. 
ATM-loss reduces binding of NRF2 to antioxidant
response elements
In the absence of any defect in the regulation of NRF2
protein levels, we considered whether the transcriptional
deregulation in ATM-null CLL tumors arises at the point
of NRF2 binding to AREs. We used XChIP and Q-PCR to
measure tBHQ-induced binding of NRF2 to an ARE in the
promoter region of the prototypic NRF2 target gene
NQO1. Consistent with the observed difference in gene
A. Agathanggelou et al.
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Figure 3. ATM-null cells are targeted by pro-oxidants in vivo. (A)
Subcutaneous xenografts of ATMshRNA (n=7) and GFPshRNA (n=7)
expressing CII-isogeneic cell lines were treated with 6 mg/kg
parthenolide or vehicle by intraperitoneal injection for five days lead-
ing to a significant reduction in tumor volume. Tumor volume was
calculated using the formula Vol = 0.5 x L x W2 before and after treat-
ment. (B) Xenografts of ATM-null primary chronic lymphocytic
leukemia were established and treated by oral gavage with vehicle
(n=5) or 100 mg/kg dimethylaminoparthenolide (DMAPT) (n=5) for
nine days, leading to a significant reduced splenic tumor burden in
DMAPT-treated animals, as determined by flow cytometry using anti-
bodies against hCD19 (cl.HIB19), hCD3 (cl.SK7), hCD45 (cl.2D1) and
mCD45 (cl.30-F11) (eBioscience Inc., San Diego, CA, USA) and
CountBright absolute counting beads (Life Technologies). (C)
Histological sections depicting differentially increased splenic 8-oxo-
dG expression in DMAPT treated xenografts. Brown labeling indi-
cates immobilization of anti-hCD19 (eBioscience) and anti-8-oxo-dG
(Abcam) antibodies. Nuclei were counterstained blue with
Hematocylin and images were captured at 200x magnification.
Statistical significance was determined using Student’s t-test.
*P<0.05 was considered significant. Error bars represent SEM.
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Figure 4. Pro-oxidant treatment induces caspase-independent, AIF-dependent apoptosis. Representative ATM-null primary CLL tumors were
treated with (A) NAPQI or (B) H2O2 for 24 h in the presence or absence of 20 mM pan-caspase inhibitor (Z-VAD-FMK). The effect on apoptosis
was analyzed using Annexin-V/PI labeling and flow cytometry. (C) Isogenic CII CLL cell lines were treated with NAPQI with and without antiox-
idant (NAC) for 24 h or irradiated (IR) and PARP cleavage induction visualized by immunoblotting. Anti-ATM (cl.11G12, Abcam), demonstrates
ATM-knockdown and anti-ACTIN antibody (Sigma) was used as the loading control. (D) Immunofluorescence labeling shows colocalization of
AIF (rabbit anti-AIF, Santa Cruz) (green) with mitochondria (MitotrackerRed, Life Technologies) (red). Nuclei were counterstained with DAPI
(blue). (E) ATM-wt and ATM-null primary CLL cells were treated with 10 mM and 40 mM H2O2 for 6 h and labeled with anti-AIF antibody.
Histogram shows quantification of cells with nuclear AIF.  (F) Immunoblot of cellular fractions generated from cells treated with 10 mM or 40
mM H2O2 confirms increased H2O2-induced nuclear localization of AIF in ATM-null CLL. (G) The AIF-inhibitor, N-phenylmaleimide (50µM AIFi)
reduced the generation of ∼50kb DNA fragments in H2O2-treated primary CLL tumors. Agarose plugs containing cells treated as indicated
were subjected to pulsed field gel electrophoresis as described32 and the separated DNA was visualized with ethidium bromide.  The statistical
significance was determined using Student’s t-test. *P<0.05 was considered significant. Error bars represent SEM.
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induction, significantly less NRF2 bound to the promoter
region of NQO1 in ATM-null CLL compared to wild-type
tumors (Figure 1E). This suggests that the reduced NRF2
dependent transcription in ATM-null primary CLL cells is
caused by defective binding of NRF2 to AREs.
ATM-null CLL cells exhibit reduced antioxidant 
capacity, elevated mitochondrial superoxide and
increased sensitivity to pro-oxidants
In agreement with the effect on antioxidant transcrip-
tional responses, the level of total cellular glutathione was
significantly lower in ATM-null compared to ATM-wt
primary CLL (Figure 2A). This effect was recapitulated in
three isogenic CLL cell lines with stable knockdown of
ATM (Online Supplementary Figure S6A).
The regeneration of GSH from GSSG is catalyzed by
glutathione reductase (GSR) utilizing NADPH as a co-fac-
tor. In ATM-wt tumors, virtually all glutathione was in
the reduced form (GSH) whereas in ATM-null tumors
only 70% was reduced and 30% was oxidized (GSSG),
indicating increased oxidative stress in these cells (Figure
2B). Accordingly, the pool of NADP+ was significantly ele-
vated in ATM-null compared to ATM-wt CLLs (Figure
2C). 
A-T cells display continuous oxidative stress due to
intrinsic mitochondrial dysfunction and contain elevated
superoxide levels.28 To determine whether ATM-null CLL
cells share this phenotype, the levels of mitochondrial
ROS were examined using the mitochondrial superoxide
sensitive dye, MitoSox Red. Consistent with observations
in A-T cells, mitochondrial ROS levels were significantly
higher in ATM-null (n=3) than wild-type CLLs (n=3)
(P=0.007) (Figure 2D and E).
Increased mitochondrial ROS damages the organelle
promoting further dysfunction in a positive-feedback
loop.28 To test whether this occurs in ATM-null CLLs,
tumors were exposed to extracellular ROS. H2O2 induced
significantly higher levels of mitochondrial superoxide in
ATM-null CLLs (n=3) compared to wild-type CLLs (n=3)
at all concentrations tested (Figure 2E). This suggests that
the intrinsic mitochondrial dysfunction associated with
ATM-deficiency can be further exacerbated using exoge-
nous sources of ROS. Examination of mitochondrial DNA
content showed that both ATM-null and ATM-wt CLL
contained a comparable number of mitochondria but sig-
nificantly more than PBMCs from normal donors (Online
Supplementary Figure S6B) indicating that the increased
mitochondrial ROS in ATM-null CLL is the result of mito-
chondrial dysfunction rather than mitochondrial number.
These data suggest that ATM-null CLL cells are under
greater oxidative stress than their wild-type counterparts.
ATM-null CLL cells show increased sensitivity 
to pro-oxidants in vitro and in vivo
In view of the increased oxidative stress in ATM-null
CLL cells, we determined if this translated to increased
sensitivity to pro-oxidant treatment. ATM-null CLLs
(n=6) were significantly more sensitive to H2O2 than
ATM-wt CLLs (n=9) in vitro (Figure 2F). The effect of
ATM-deficiency on H2O2 -sensitivity was confirmed in a
CII-isogenic cell line with stable knockdown of ATM
(Online Supplementary Figure S7A).
Next, we addressed the sensitivity of ATM-null and
wild-type primary CLLs to NAPQI and parthenolide, pro-
oxidants that induce oxidative stress by depleting glu-
tathione (GSH).29,30 ATM-null tumors were significantly
more sensitive than wild-type to both reagents (Figure 2G
and 2H). The effects of H2O2, NAPQI and parthenolide
were associated with oxidative damage, as treatment
with N-acetyl cysteine (NAC), a glutathione precursor,
protected cells (Online Supplementary Figure S7B-D).
Importantly, the tumor-specific activity of both H2O2 and
parthenolide was confirmed using PBMCs from normal
donors (Online Supplementary Figure S7E and F).
To determine if the increased sensitivity to pro-oxi-
dants was specific to the ATM-null status, we examined
primary CLL cells with monoallelic 11q deletion or TP53
mutations. The sensitivity of CLLs with either genotype
did not significantly deviate from wild-type CLLs, sug-
gesting that increased sensitivity to pro-oxidants is specif-
ically associated with the ATM functional loss (Online
Supplementary Figure S7G and H). 
The in vivo efficacy of pro-oxidant therapy on ATM-
deficient CLL was examined using two murine xenograft
models. First, a subcutaneous xenograft model of CII-iso-
genic cell lines with and without stable ATM-knockdown
was established.  Parthenolide significantly inhibited the
growth of ATM-knockdown tumors compared to either
vehicle treated cells or to parthenolide treated wild-type
tumors (44.0% vs. 9.7%) (Figure 3A). 
Finally, an ATM-null primary CLL xenograft was estab-
lished, and for systemic pro-oxidant treatment, dimethy-
lamino parthenolide-hydrochloride (DMAPT-HCl), a
water-soluble and orally bioavailable form of partheno-
lide,31 was generated.  Quantification of engrafted splenic
CLL cells demonstrated that pro-oxidant therapy signifi-
cantly reduced hCD19+ tumor cell burden (P<0.05) (Figure
3B). Furthermore, engrafted cells displayed increased lev-
els of 8-oxo-dG, indicating oxidative stress was induced
following pro-oxidant treatment (Figure 3C).
These data show that pro-oxidant based therapies are
effective against chemoresistant ATM-null CLL tumors in
vitro and in vivo. 
Pro-oxidant induced cell death in CLL is 
p53/caspase-independent and involves AIF
Since the DDR is defective in ATM-null CLL, a DDR-
independent pathway must be operating to facilitate pro-
oxidant induced cell death. Consistent with this, activa-
tion of the DDR was not detected in either ATM-null or
wild-type CLL cells following treatment with therapeuti-
cally effective concentrations of H2O2 (Online
Supplementary Figure S8), NAPQI or parthenolide (data not
shown). To elucidate the mechanism of cell death induced
by pro-oxidants, ATM-null primary CLL tumors were
treated with NAPQI or H2O2 with and without pan-cas-
pase inhibitor. Caspase inhibition did not significantly
affect NAPQI or H2O2 -induced cell death of ATM-null pri-
mary CLL tumors (Figure 4A and B). This was confirmed
by immunoblotting in CII-isogenic cell lines which
showed that, in contrast to ionising radiation, PARP1-
cleavage was not induced by NAPQI (Figure 4C). 
Next, we investigated the induction of cell death by an
alternative mechanism involving the cellular redistribu-
tion of AIF. In response to stress, AIF is released from the
mitochondria as a cleaved 57kDa pro-apoptotic protein
(tAIF) that translocates to the nucleus where it co-oper-
ates with endonuclease G to cause large-scale DNA frag-
mentation and chromatin condensation.33 In untreated
cells, AIF staining co-localized with mitochondria (Figure
A. Agathanggelou et al.
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4D), whereas treatment with H2O2 led to nuclear translo-
cation (Figure 4E and F). In agreement with the differen-
tial sensitivity of ATM-null CLL tumors to pro-oxidants,
nuclear tAIF was induced with 10 mM H2O2, whereas in
ATM-wt CLLs, 40 mM H2O2 was required to elicit the
same effect (Figure 4F). Inhibition of AIF prevented H2O2-
induced digestion of genomic DNA into ∼50kb frag-
ments, thus confirming the role of AIF in this process
(Figure 4G). 
These data demonstrate that pro-oxidants induce p53
and caspase-independent cell death in wild-type and
ATM-null CLL associated with nuclear translocation of
AIF. 
Discussion
We show that the ATM-null phenotype in CLL can be
targeted with pro-oxidant based therapies to induce selec-
tive killing. We demonstrate that a defect in the NRF2-
directed antioxidant response is present in ATM-null pri-
mary CLLs. This correlated with reduced antioxidant
capacity, increased mitochondrial ROS and increased sen-
sitivity to pro-oxidants in vitro and in vivo.  Previous
reports have demonstrated increased sensitivity of CLL
cells to pro-oxidant based therapies compared to non-
tumor cells, but this is the first study to demonstrate that
this approach specifically targets the ATM-null pheno-
type in CLL.34,35  
Our data suggest that binding of NRF2 to target gene
AREs is reduced in ATM-null CLL despite normal levels of
NRF2, KEAP1, BACH1 and MAF proteins and normal lev-
els of NRF2/MAF heterodimerization. Previous studies
indicated that reduced PKCδ levels might contribute to
defective Nrf-2 regulation in Atm-/- mice and that NRF2
stability is regulated by phosphorylation at ser40 by
PKC.14,21 We observed that PKCδ and serine-phosphory-
lated NRF2 levels are unaffected by the loss of ATM in
CLL cells and that in agreement with previous proteomic
screen,10 both PKCδ and NRF2 are unlikely to be ATM
substrates. In search for the mechanism of reduced NRF2
activity in ATM null cells, we confirmed the role of
BRCA1 in the regulation of the NRF2 antioxidant
response. Furthermore, by showing that the combined
knockdown of ATM and BRCA1 does not cause further
deregulation, we demonstrate that ATM and BRCA1
function in the same pathway to regulate NRF2-antioxi-
dant responses. Previously, we have reported that ATM-
null tumors are refractory to conventional DNA damag-
ing therapies due to inactivation of the p53-dependent
apoptosis pathway,1,36 underscoring the need for a p53-
independent strategy for the treatment of these tumors.
In this study, we found that ATM-null cells are differen-
tially sensitive to pro-oxidants as reflected by the appear-
ance of tAIF in the nuclei of these cells at lower concen-
trations of H2O2 than in ATM-wt cells. The higher level of
mitochondrial superoxide in ATM-null CLLs indicated
mitochondrial dysfunction. Pro-oxidant treatment is like-
ly to further damage the mitochondria, thus triggering the
translocation of AIF and p53-independent cell death.
Recent studies also suggest AIF translocation may occur
due to an increase in inducible nitric oxide synthase
(iNOS) activity following stimulation of JNK by ROS and
the subsequent activation of ERK1/2.37 In addition, ROS
can induce the caspase-independent activation of the BH3
interacting domain death agonist (BID), thus leading to
AIF translocation.38 
Most importantly, using a pro-oxidant based strategy,
we show that ATM-null CLL cells are significantly more
sensitive than ATM-wt tumors and non-tumor cells to
agents previously shown to stimulate NRF2-mediated
adaptation to stress.39,40 Thus both NAPQI and partheno-
lide represent novel clinically applicable approaches for
the treatment of ATM-null CLL. Of note, acetaminophen,
the NAPQI precursor, has previously been used in a phase
I trial for the treatment of metastatic melanoma41 as an
approach to enhance the specificity of anti-cancer agents
which deplete glutathione. Similarly, parthenolide and its
water soluble derivative, DMAPT, have been shown to
have activity against hematopoietic malignancies, includ-
ing chemo-refractory CLL and acute myeloid
leukemia.42,43
Targeting oxidative stress to bypass the defect in p53-
dependent apoptosis is an attractive therapeutic strategy
for several reasons. First, genetic variations present a chal-
lenging problem with respect to the treatment of CLL8,44
and elevated oxidative stress can impact on disease pro-
gression by inducing oxidative DNA damage45 and
increasing the mutation rate that supports clonal diversi-
ty. Indeed, in CLL, oxidative stress is present early in the
genesis of disease and is detectable at the stage of pre-
malignant monoclonal B-lymphocytosis.46 Thus to avoid
the selection of adverse subclones with ATM-deficiency
that occurs with conventional genotoxic agents,7,8 it is
preferable to target stress phenotypes common to all
tumor cells and, as in this case, potential mechanisms of
diversification.47 Furthermore, elevated oxidative stress
may provide a selective advantage for ATM-null CLL cells
regarding their interactions with immune cells within
lymphoid tissues. The activity of surrounding immune
cells is suppressed by ROS and, therefore, loss of ATM
and the associated increase in ROS production may facil-
itate immune evasion.48 Finally, loss of ATM and the asso-
ciated decrease in antioxidant levels may render the
tumor cells more dependent on stromal cells for redox
support,49 thus providing a rationale for combined thera-
peutic approaches with pro-oxidants and inhibitors of
tumor/microenvironment interactions. 
Recently a number of p53-indendent treatments for
CLL became available. These include use of
immunomodulatory agents as well as inhibitors of B-cell
receptor signaling that target either Bruton tyrosine
kinase (ibrutininb) or PI3 kinase delta (idelalisib).50 Pro-
oxidant based therapies utilize oxidative stress as a cellu-
lar weakness of leukemic cells and represent an example
of a synthetic lethality approach. It will be of interest to
determine whether pro-oxidants could be used in combi-
nation with new targeted treatments to increase the ben-
efit for patients with the ATM-null CLL phenotype.
Finally, it is important to note that the roles in DDR and
oxidative stress responses denote two separate ATM
functions. ATM is activated by oxidation of the cysteine
residue at position 2991 in the FATC domain leading to
formation of disulphide cross-linked dimers.19 ATM
mutated at C2991 is unresponsive to oxidative stress
despite normal response to DNA damage. This raises the
possibility that certain ATM mutations may not affect
DDR and still render a phenotype amenable for targeting
by pro-oxidants. 
In summary, we show that the oxidative stress pheno-
ATM-null CLLs are sensitive to pro-oxidants
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